Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CXMGC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Isotype-SG3376
|
|||||
| Synonyms |
Isotype-SG3376
Click to Show/Hide
|
|||||
| Organization |
CL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK; UCL Cancer Institute, 72 Huntley Street, London, UK.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
SG3249
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2288.3 pM | Positive CD45 expression (CD45+++/++) | ||
| Method Description |
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.
Click to Show/Hide
|
||||
| In Vitro Model | Acute erythroid leukemia | OCIM1 cells | CVCL_2149 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3399.8 pM | Positive CD45 expression (CD45+++/++) | ||
| Method Description |
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.
Click to Show/Hide
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 6000 pM | Negative CD45 expression (CD45-) | ||
| Method Description |
Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.
Click to Show/Hide
|
||||
| In Vitro Model | Normal | 293T cells | CVCL_0063 | ||
References